UnknownNCT05109585

Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Collegium Medicum w Bydgoszczy
Principal Investigator
Jacek Kubica, Prof.
Collegium Medicum w Bydgoszczy
Intervention
assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule(diagnostic_test)
Enrollment
1000 target
Eligibility
18 years · All sexes
Timeline
20212022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05109585 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials